Advances in the management of multiple sclerosis spasticity: Recent clinical trials

European Neurology

Volumn 72, Issue , 2014, Pages 9-11

  Fernández, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Cognition; Mood; Phase 4 study; Pivotal trial; Spasticity; THC: CBD oromucosal spray

Indexed keywords

NABIXIMOLS; PLACEBO; CENTRAL MUSCLE RELAXANT; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

AEROSOL; ARTICLE; BECK DEPRESSION INVENTORY; CANNABIS USE; CAREGIVER; CLINICAL TRIAL (TOPIC); COGNITION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; MOOD; MULTIPLE SCLEROSIS; ORAL SPRAY; PATIENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPASTICITY; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; AFFECT; DRUG EFFECTS; MUSCLE SPASTICITY; PATHOPHYSIOLOGY; PSYCHOLOGY;

AFFECT; CLINICAL TRIALS, PHASE III AS TOPIC; COGNITION; HUMANS; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84910028087     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000367616     Document Type: Article

References (8)

1. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J: Natural history of multiple sclerosis symptoms. Int J MS Care 2013; 15: 146-158.
2. Oreja-Guevara C: Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 2012; 12(suppl 4):3-8.
3. DGN/KKNMS Leitlinie zur Diagnose und Therapie der MS. Guidelines for MS diagnosis and treatment, 2012. Available at: http://www.dmsg.de/dokumentearchiv/dgnkknms-msll-20120412-final.pdf [Accessed June 2014].
4. Oreja-Guevara C, Montalban X, de Andrés C, Casanova-Estruch B, Muñoz-García D, García I, Fernández Ó; Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología: Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología [Article in Spanish]. Rev Neurol 2013; 57: 359-373.
5. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296.
6. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459.
7. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols ∗ (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131.
8. Wright S, Vachova MM, Novakova I: The effect of long-term treatment with a prescription cannabis-based THC: CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to multiple sclerosis [Poster 1206]. Mult Scler 2013; 19(suppl 1): 559-573.